A T Cell Inflammatory Phenotype is Associated with Autoimmune Toxicity of the PI3K Inhibitor Duvelisib in Chronic Lymphocytic Leukemia

[1]  S. Tyekucheva,et al.  A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients , 2020, Leukemia.

[2]  Thomas G. Dietterich.  What is machine learning? , 2015, Archives of Disease in Childhood.

[3]  Stephen Li,et al.  Automated Data Cleanup for Mass Cytometry , 2019, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[4]  S. Tyekucheva,et al.  Imbalance in T Cell Subsets Triggers the Autoimmune Toxicity of PI3K Inhibitors in CLL , 2019, Blood.

[5]  A. Zelenetz,et al.  Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  I. Flinn,et al.  DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  F. Bosch,et al.  The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. , 2018, Blood.

[8]  J. Ritz,et al.  Mass Cytometry Identifies T Cell Populations Associated with Severe Hepatotoxicity in CLL Patients on Upfront Idelalisib , 2018, Blood.

[9]  Mark D. Robinson,et al.  Compensation of Signal Spillover in Suspension and Imaging Mass Cytometry , 2018, Cell systems.

[10]  A. Zelenetz,et al.  Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib , 2017, Leukemia.

[11]  J. Lieberman,et al.  Human regulatory T cells undergo self-inflicted damage via granzyme pathways upon activation. , 2017, JCI insight.

[12]  Philippe Foubert,et al.  PI3Kγ is a molecular switch that controls immune suppression , 2016, Nature.

[13]  Hao Chen,et al.  Cytofkit: A Bioconductor Package for an Integrated Mass Cytometry Data Analysis Pipeline , 2016, PLoS Comput. Biol..

[14]  L. Rassenti,et al.  Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. , 2016, Blood.

[15]  Eli R. Zunder,et al.  Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm , 2015, Nature Protocols.

[16]  Bonnie Tillotson,et al.  PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. , 2013, Chemistry & biology.

[17]  Sean C. Bendall,et al.  Normalization of mass cytometry data with bead standards , 2013, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[18]  Xiangpei Li,et al.  CD4+CD25+CD127low/− T Cells: A More Specific Treg Population in Human Peripheral Blood , 2012, Inflammation.

[19]  J. Flint,et al.  Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties , 2010, Proceedings of the National Academy of Sciences.

[20]  Davis J. McCarthy,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[21]  D. Littman,et al.  The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells , 2006, Cell.

[22]  Laurens van der Maaten,et al.  Accelerating t-SNE using tree-based algorithms , 2014, J. Mach. Learn. Res..

[23]  D. Littman,et al.  The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. , 2006, Cell.